Borneol: A Comprehensive Reference
1. Identity and Chemical Characterization
Names and Classification
Borneol is an alcohol belonging to the terpene family with the chemical formula C10H18O. More precisely, borneol is a chiral bicyclic alcohol that exists in nature as two enantiomers, (–)- or L-borneol and (+)- or D-borneol. Both borneol and isoborneol belong to the category of 2-bornanol, a derivative of bornane. Borneol is oxidized to the ketone camphor, and this close structural relationship explains why borneol is sometimes called "borneol camphor" in older literature.
The compound was identified and formally named camphre de Bornéo, or Borneo camphor, in 1842 by the French chemist Charles Frédéric Gerhardt. In the 1870s, English chemist Henry E. Armstrong and others measured the properties and reactions of borneol (which he called "camphol") and related compounds. The 19th-century chemists did not realize that borneol existed in two isomers, and their publications are listed under racemic borneol.
Its Chinese name is bingpian (冰片). The typical appearance of borneol gives the compound its Chinese name bingpian, wherein "bing" denotes ice and "pian" means slice. Its historical Chinese trade name is long nao xiang ("dragon's brain camphor"). Natural borneol, known as "Borneo camphor" or "dragon's brain camphor," was historically obtained from Dryobalanops aromatica, a tree native to Borneo and Sumatra.
Stereoisomerism and Forms
Being chiral, borneol exists as enantiomers, both of which are found in nature: d-borneol (also written (+)-borneol, dextroborneol, dexborneol) and l-borneol (or (−)-borneol, levoborneol). Some sources such as PubChem and ChEBI use the term borneol to refer to the entire category of 2-bornanols, while others such as KEGG use the term borneol to refer to the compounds with endo hydroxyl only. There is also a third isomer called isoborneol that is employed in specific procedures in organic chemistry.
The 2020 version of the Chinese Pharmacopoeia has established standards on L-borneol, D-borneol, and synthetic borneol (a mixture of L-borneol, D-borneol, D-isoborneol and L-isoborneol) regarding their physical characteristics. Synthetic borneol (SB) is obtained by a reduction of camphor or the esterification and hydrolysis of α-pinene in turpentine; it contains not only (±)-borneol, but also considerable quantities of isoborneol, which has shown potent mucosal irritation and liver toxicity.
Physical Properties
This naturally occurring organic compound has a white color with a scent similar to camphor. In its unadulterated form, borneol is crystalline, composed of many small, irregularly shaped crystals. Borneol's melting and boiling temperatures are very close to each other; as a result, when the compound is heated to approximately 207 °C, it melts and sublimes.
Biosynthesis
(−)-Borneol belongs to a bicyclic monoterpene compound; the cytosolic MVA pathway and the plastidial 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway produce isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate (DMAPP), which are general substrates of terpenoids; they produce the monoterpene precursor geranyl diphosphate (GPP), which is cyclized by the monoterpene synthase and dephosphorylated to produce (−)-borneol. The chirality of borneol in a plant depends on the preferred chirality of the bornyl diphosphate synthase.
2. Natural Sources
Primary Botanical Sources
Borneol can be found in several species of Heterotheca, Artemisia, Rosmarinus officinalis (rosemary), Dryobalanops aromatica, Blumea balsamifera, and Kaempferia galanga. It also occurs naturally in cinnamon leaf, ginger, Thymus, cardamom, coriander leaf, and coriander seed. Natural (−)-borneol occurs in Blumea balsamifera.
Along with eucalyptol (1,8-cineole), camphor, and α-pinene, (−)-borneol is a principal component of the oil and leaves of the herb rosemary (Salvia rosmarinus, formerly Rosmarinus officinalis). As a bicyclic monoterpene belonging to the class of camphene, borneol is sourced from Blumea balsamifera, Cinnamomum camphora (L.) Presl, Dryobalanops aromatica Gaertner, and the volatile oils extracted from various other plant sources.
Commercial and Synthetic Production
The synthesis of borneol is preferred to its extraction because it is not present in sufficient quantities in essential oils to make extraction economically viable. Synthetic borneol is most commonly prepared from camphor or from α-pinene derived from turpentine. Borneol is also used as a food additive permitted for direct addition to food for human consumption.
3. Traditional and Historical Use
East Asian Antiquity and Traditional Chinese Medicine
Borneol should be considered a well-deserved representative of the ethnic medicine and cultural exchange between the East and the West, traceable to the classical age. It has been traded to China since the Han dynasty from Kalimantan Island, once called Borneo, which may be the origin of its nomenclature. Borneol was first recorded in the Ming Yi Bie Lu, one of the earliest books of Chinese herbal medicine, and has since been recorded in the subsequent works of Chinese Materia Medica, up to the current version of the Chinese Pharmacopoeia (2020 Edition).
This precious crystalline material was found in cracks and cavities within the trunk of mature trees and was traded throughout Asia as early as the 5th century CE for its medicinal properties and use in religious ceremonies. Borneol was then recorded in the Supplementary Records of Famous Physicians and featured in the Newly Revised Materia Medica in the Tang dynasty (China, 618–907 CE).
The heart, spleen, and lung meridians correspond to borneol, which is described as pungent, bitter, and slightly chilly in the Chinese Pharmacopoeia (2020 edition). It is said to eliminate heat, awaken the mind, open orifices, and relieve pain, and is used to treat coma, chest paralysis and heartache, red eyes and mouth sores, sore throat, and ear canal pus. Additionally, it is used to treat severe syncope, phlegm syncope, and syncope caused by stroke.
In TCM, borneol is used in the form of moxa, an early account of which is available in the Bencao Gangmu. In Chinese medicine, borneol (in the form of a raw resin) as well as artemisia are used both internally and topically. Moxa is grated artemisia that is burned on or close to the patient's body with a view to generate local heating, in addition to producing an effect from the substance itself.
Borneol has been used in Arabia since medieval times and in Germany since the 12th century, and is now widely applied throughout the world as both medicine and perfume.
Dosage in Traditional Formulations
Because the resin is strongly aromatic and historically high-priced, the recommended dosage is quite small. Many herb guides list the internal dosage as 30 to 100 mg, taken in powders or pills (if added to a decoction, it will all evaporate). The Pharmacopeia of the People's Republic of China indicates 150 to 300 mg per day. The largest amount of borneol used in a traditional-style formula is in Guanxin Suhe Wan, a patent remedy that is a modern version of the traditional prescription Suhexiang Wan from the He Ji Ju Fang.
Ayurvedic Tradition
Borneol has a long history of application in different medicinal systems, such as Traditional Chinese Medicine (TCM) and Ayurveda. In Ayurveda, borneol is called "Pachha Karpooram" and is used for its carminative, analgesic, and antispasmodic properties, having been utilized to treat digestive disorders, nervous system disorders, and skin conditions.
4. Key Constituents, Active Compounds, and Mechanisms of Action
Blood–Brain Barrier Permeability Enhancement
Borneol is a naturally occurring compound in a class of "orifice-opening" agents often used for resuscitative purposes in traditional Chinese medicine. A growing body of evidence confirms that the "orifice-opening" effect of borneol is principally derived from opening the blood–brain barrier (BBB). Borneol is therefore believed to be an effective adjuvant that can improve drug delivery to the brain.
The permeability-enhancing effects of borneol may be achieved mainly via three mechanisms: the inhibition of efflux protein function; the enhancement of transmembrane tight junction protein; and predominant enhancement of vasodilatory neurotransmitters.
Borneol is able to penetrate the blood–brain barrier, affecting signal transmission between the BBB and the microenvironment of the brain, downregulating the expression of inflammatory and oxidative stress proteins in the neurovascular unit (NVU), especially in microglia and astrocytes. In summary, borneol is a potential drug delivery agent for drugs against neurodegenerative diseases.
GABAergic and Receptor-Mediated Mechanisms
Borneol plays a neuroprotective role by reducing glutamate levels, activating the GABAA receptor, and blocking the necrosis and apoptosis of neurons. Both D-borneol and L-borneol were shown to enhance the actions of γ-aminobutyric acid (GABA) at recombinant GABAA receptors and had moderate direct action on these receptors (Granger et al., 2005). D-borneol has neuroprotective effects after primary neuronal injury induced by glutamate at low concentrations, and this effect is consistent with the activation of the GABAA receptor.
Transient receptor potential melastatin 8 (TRPM8) channel is a pharmacological target of borneol and mediates its therapeutic effect in the eyes. Borneol can activate the cold-sensing TRPM8 channel and modestly increase ocular surface wetness, suggesting it is an active compound in ophthalmic preparations and particularly useful in treating dry eye syndrome.
Anti-Inflammatory Mechanisms
Borneol can reduce the transcription and expression of genes related to inflammatory factors such as bradykinin, IL-1β, TNF-α, and NGF by downregulating the expression of NF-κB-related proteins such as IKKα/β and IκBα. It inhibits the activation of PLC-PKC and MARK signaling pathways mediated by TrkA, TNFR, and IL-1R, and suppresses the phosphorylation of TRPV1, as well as the activation of GPCR and ASIC, thus exerting an analgesic effect.
From an immunological perspective, borneol can mitigate the onset and progression of inflammation by inhibiting the production of inflammatory mediators, reducing nitric oxide synthesis, curtailing oxidative stress, limiting the migration and infiltration of inflammatory cells, and promoting the resolution of inflammation.
Antioxidant Mechanisms
Both L-borneol and D-borneol protected human neuroblastoma cells (SH-SY5Y) against β-amyloid-induced toxicity, exerting an antioxidative effect by increasing the expression and nuclear translocation of Nrf2 (Hur et al., 2013). Borneol combined with Salvia miltiorrhiza not only increased SOD levels and decreased MDA levels but also upregulated the expression of Nrf2 and inhibited oxidative stress. The combination of these two agents was more effective than Salvia miltiorrhiza alone, suggesting that borneol plays a synergistic role by activating the Nrf2-ARE signaling pathway in vivo.
Barrier Permeation Enhancement Beyond the BBB
Borneol has been proven to enhance the permeability of biological barriers such as the blood–brain, transdermal, corneal, and intestinal barriers. Studies have revealed that L-borneol is more effective than D-borneol in enhancing the penetration of hydrophilic drugs, primarily by modulating P-glycoprotein (P-gp) activity. Moreover, L-borneol exhibits a stronger binding affinity for the CYP2C9 target, which may be associated with its anti-myocardial ischemia effects through the regulation of arachidonic acid metabolism.
Enantiomer-Specific Activity Differences
L-borneol's key biological activities include drug penetration enhancement, neuroprotection, cardioprotection, antibacterial adhesion, acute toxicity modulation, and tumor sensitivity regulation. Notably, (−)-borneol exhibits superior permeation-enhancing, neuroprotective, and cardioprotective effects compared to (+)-borneol (D-borneol), as demonstrated in preclinical studies. Conversely, D-borneol has been noted to demonstrate superior anti-tumor properties in comparative analyses.
5. Scientific Evidence by Area of Use
5.1 Blood–Brain Barrier Modulation and CNS Drug Delivery
This is the most extensively studied area for borneol in modern science. A preclinical systematic review and meta-analysis assessed the evidence and possible mechanisms of borneol for improving co-administered CNS drug delivery in animal models. The electronic literature search was conducted in six databases; 58 studies with 63 comparisons involving 1,137 animals were included. Among 47 studies reporting assessments of CNS drug concentration, 45 studies showed significant effects of borneol for improving CNS drug delivery (p < 0.05), whereas 2 studies showed no difference.
Seven studies reported safety, in which one study showed borneol produced reversible changes in BBB penetration; six studies showed borneol did not increase co-administration of blood drug concentrations in peripheral tissues (p > 0.05). Effects of borneol are closely associated with inhibition of efflux protein function, release of tight junction protein, increase of vasodilatory neurotransmitters, and inhibition of active transport by ion channels. In conclusion, borneol is a promising candidate for CNS drug delivery, mainly through mediating multi-targeted BBB permeability.
Strength of evidence: The current evidence base is almost entirely preclinical (animal models and in vitro cell studies). Insufficient evidence and unknown mechanisms continue to limit the application of borneol in clinical settings. No large-scale human randomized controlled trials (RCTs) have been identified in the published literature establishing its clinical efficacy as a BBB-opening drug delivery adjuvant.
5.2 Neuroprotection in Ischemic Stroke
A systematic review aimed to assess preclinical evidence of borneol for experimental ischemic stroke, focused on regulating BBB permeability. Seven databases were searched from inception to July 2018; studies of borneol for ischemic stroke in animal models were included. The administration of borneol produced a significant decrease of BBB permeability during cerebral ischemic injury according to brain Evans blue content and brain water content compared with controls (P < 0.01). In addition, borneol improved neurological function scores and cerebral infarction area. Borneol may be a promising neuroprotective agent for cerebral ischemic injury, largely through alleviating BBB disruption, reducing oxidative reactions, inhibiting inflammation, inhibiting apoptosis, and improving the activity of lactate dehydrogenase as well as P-glycoprotein and NO signaling pathways.
Borneol exhibits promise in bidirectionally modulating the BBB under pathological conditions, suggesting potential clinical applications for related diseases. Methods involved searching PubMed, CNKI, and Wanfang Data for articles on animal experiments and cell-based research published from January 2003 to May 2023. It is believed that in the future, more effective and targeted therapies for cerebral glioma and ischemic stroke will be explored relating to the protective mechanism of the BBB under pathological conditions with borneol alone or in combination with other drugs.
Strength of evidence: All published systematic reviews draw on animal and in vitro data exclusively. Human clinical trial evidence for stroke treatment is not yet established.
5.3 Analgesic (Pain-Relieving) Effects
A 2025 review synthesized preclinical evidence demonstrating borneol's dual analgesic pathways: (1) receptor-mediated actions (e.g., TRPM8 activation, GABA agonism) and (2) immune modulation (e.g., NF-κB suppression, ROS inhibition).
Borneol can inhibit the production of NO by suppressing the activity of nitric oxide synthase, and then inhibit the phosphorylation of TRPV1 by suppressing the phosphorylation of PKG. Borneol can also inhibit the production of inflammasomes and the inflammatory mediators such as IL-1β and IL-18 mediated by them by inhibiting the synthesis of ROS.
The analgesic efficacy of borneol appears to involve the synergistic action of receptor and immune mechanisms, rather than isolated effects. The analgesic effect has been substantiated in various rodent models.
Strength of evidence: Borneol's analgesic potential remains unverified in behavioral tests (e.g., hot plate, cold plate, von Frey assays) in humans, despite in vitro evidence suggesting modulation of TRPA1, GABA receptors, oxidative stress (ROS), and inflammatory pathways (IL-1β, IL-6, NO). Evidence is preclinical only.
5.4 Antimicrobial Activity
Many studies have revealed a promising antimicrobial, antiparasitic, and antimicrobial adhesion activity of borneol. One study demonstrated significant differences in antibacterial properties of D-borneol, L-borneol, and synthetic borneol against Staphylococcus aureus, β-Streptococcus hemolytic and Escherichia coli (Luo et al., 2014), with D-borneol and L-borneol showing enhanced ability to inhibit bacterial growth compared to synthetic borneol. The antimicrobial actions of the three compounds were observed at low concentrations, and sterilization was reported at high concentrations.
Borneol has shown exceptional antibacterial activity and has been incorporated in TCM formulas for external use against bacteria growth, particularly as a treatment approach to chronic eczema. However, a knowledge gap still exists within the compositions of various sources of borneol and their mechanisms of analgesic and antimicrobial activity.
Strength of evidence: Evidence is primarily in vitro (laboratory-based minimum inhibitory concentration and cell-based studies). No human clinical trials specifically evaluating borneol's antimicrobial efficacy as a standalone agent have been identified.
5.5 Ophthalmic Applications and Dry Eye
In China, borneol is widely used in ophthalmic preparations and classic TCM formulas to treat various diseases including oculopathies, oral ulcers, sore throat, skin diseases, and mild neurological disorders, and has been found to produce anti-inflammatory, antibacterial, and analgesic effects. Borneol-containing eye drops account for a large proportion of over-the-counter (OTC) eye drops sold in China.
The TRPM8 channel is a pharmacological target of borneol and mediates its therapeutic effect in the eyes. Borneol can activate the cold-sensing TRPM8 channel and modestly increase ocular surface wetness, suggesting it is an active compound in ophthalmic preparations and particularly useful in treating dry eye syndrome.
Borneol is widely used in ophthalmic preparations in China, though little is known about its exact function.
Strength of evidence: The TRPM8 activation mechanism has been identified through in vitro and animal research. Human clinical data specific to borneol in ophthalmic preparations is very limited in the English-language peer-reviewed literature, despite widespread traditional and commercial use in China.
5.6 Cardiovascular and Cardio-Cerebrovascular Diseases
Modern medicine has established that borneol exhibits a range of pharmacological activities used in the treatment of many diseases, particularly cardio-cerebrovascular diseases (CVDs). The crucial role of borneol in enhancing drug delivery and improving bioavailability has attracted much attention.
Borneol is usually used as a "guide drug" in prescriptions to direct the bioactive components of herbs to the proper organs to exert a harmonizing effect. A better therapeutic effect has been observed for the combined administration of Panax notoginseng and Radix Salvia miltiorrhiza with borneol than the single use of these herbs alone for patients with cardiovascular diseases in practice.
L-borneol has significant effects of anti-myocardial ischemia and anti-cerebral ischemia and hypoxia in mice.
Strength of evidence: Evidence derives predominantly from animal models and pharmacokinetic interaction studies in rabbits. The clinical cardiovascular evidence consists largely of traditional use data and preclinical research; large-scale controlled human trials are lacking.
5.7 Anticancer and Chemosensitization Effects
Anti-inflammatory, analgesic, neuroprotective, and antiepileptic actions of borneol have been elucidated via a number of preclinical studies. Anti-diabetic, anti-hyperlipidemic, antihypertensive, and anticancer effects have also been explored for borneol.
One preclinical study showed that borneol increased cytotoxicity in C6 and U251 glioma cells in response to temozolomide (TMZ). Through transmission electron microscopy, western blotting, and immunohistochemical tests, borneol combined with TMZ significantly increased levels of autophagy, and HIF-1α was identified as a candidate target through which borneol enhances the cytotoxic effect of TMZ. Borneol's ability to enhance HIF-1α degradation was counteracted following the administration of autophagy inhibitors. In vivo, borneol treatment enhanced the anticancer effect of TMZ and delayed tumor progression.
Results from one study showed that natural borneol strongly potentiated selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake, activation of ROS-mediated DNA damage, and inactivation of Akt and ERK. This study suggests that natural borneol could be further developed as a chemosensitizer of selenocystine in the treatment of human cancers.
The concurrent administration of natural borneol and doxorubicin (DOX) reduced the level of reactive oxygen species (ROS). Research findings indicated that natural borneol can substantially enhance the anticancer properties of paclitaxel and curcumin.
Strength of evidence: All currently available anticancer data is from cell lines and animal models. No human oncology clinical trials of borneol as a standalone or adjuvant anticancer agent have been reported in peer-reviewed literature to date.
5.8 Antiepileptic and Sedative Effects
It has been reported that borneol directly potentiates GABA activity at recombinant human α1β2γ2L GABAA receptors expressed in Xenopus laevis oocytes (Granger et al., 2005). By enhancing GABAergic activity, borneol can produce calming effects and reduce nervous system excitability, which is proposed as beneficial in conditions like anxiety and epilepsy.
Anti-inflammatory, analgesic, neuroprotective, and antiepileptic actions of borneol have been elucidated via a number of preclinical studies.
Strength of evidence: Evidence is preclinical (in vitro receptor studies and animal behavioral models). Human clinical evidence for borneol as an antiepileptic or sedative is absent from the peer-reviewed literature.
6. Body Systems and Health Areas Associated with Borneol
- Central Nervous System: The Chinese Traditional Medicine system documents almost 1,000 years of clinical use of borneol as an adjuvant as well as an active agent in treating various diseases and disorders, mainly pertaining to the central nervous system.
- Cardiovascular System: Used in classical formulations such as Suhexiang Wan and Suxiao Jiuxin pills; borneol is considered less irritating and is mainly used in eye preparations and pediatric emergency medicine, in well-known formulations such as Suhexiang pills and Suxiao Jiuxin pills, to relieve heat and discomfort.
- Ocular System: Borneol is widely used in ophthalmic preparations and classic formulas of TCM to treat various diseases including oculopathies.
- Musculoskeletal / Pain: In TCM, borneol has been used to treat respiratory conditions, heart diseases, and pain, and is also used topically to relieve muscle aches and joint pain.
- Skin / Dermatological: Borneol has been incorporated in TCM formulas for external use against bacteria growth, particularly as a treatment approach to chronic eczema.
- Respiratory Tract: Borneol's cooling and aromatic properties made it especially valuable in balms and inhalants designed to clear nasal congestion and soothe sore throats.
- Gastrointestinal: In Ayurveda, borneol is used for its carminative, analgesic, and antispasmodic properties, having been utilized to treat digestive disorders.
7. Dosage Forms and Reported Dosages
Traditional Oral Dosage
Many herb guides list the internal dosage as 30 to 100 mg, taken in powders or pills (adding it to a decoction causes it to evaporate). The Pharmacopeia of the People's Republic of China indicates 150 to 300 mg per day.
Modern Pharmaceutical Forms
Borneol has been proven to enhance the permeability of biological barriers such as the blood–brain, transdermal, corneal, and intestinal barriers, and growing interest has been shown in drug delivery system design for trans-barrier transport involving borneol. Forms under investigation or in use include:
- Topical/transdermal preparations: Incorporated into creams, ointments, and microemulsion-based transdermal systems as a permeation enhancer for co-administered drugs.
- Ophthalmic drops: Borneol-containing eye drops account for a large proportion of over-the-counter (OTC) eye drops sold in China.
- Oral pills and powders: Used in classical TCM formulas such as Suhexiang Wan and Guanxin Suhe Wan.
- Nanoparticle drug delivery systems: Borneol, as a traditional Chinese medicine, can enhance therapeutic efficacy by guiding active ingredients to the target site. Borneol reportedly improves the penetration capacity of the nasal, corneal, transdermal, intestinal, and blood–brain barriers.
The 2020 version of the Chinese Pharmacopoeia has established standards on L-borneol, D-borneol, and synthetic borneol, regarding their physical and chemical characteristics.
8. Safety Considerations
Acute Toxicity and Irritation
Borneol may cause eye, skin, and respiratory irritation, and is harmful if swallowed in large amounts. Acute exposure may cause headache, nausea, vomiting, dizziness, lightheadedness, and syncope. Exposure to higher levels or over a longer period of time may cause restlessness, difficulty concentrating, irritability, and seizures.
Borneol has been shown to have little to no irritation effect when applied to human skin at doses used in fine fragrance formulation.
Natural vs. Synthetic Borneol Safety Differential
The safety concerns of natural borneol are generally considered negligible compared to synthetic borneol. Synthetic borneol contains not only (±)-borneol, but also considerable quantities of isoborneol, which has shown potent mucosal irritation and liver toxicity. Furthermore, (±)-borneol in synthetic borneol is easily transformed into toxic camphor during storage.
Reproductive Toxicity
It has been reported in animal studies that high dosages of synthetic borneol significantly reduced the fertility of mice compared to D-borneol, leading to abortion of mid- to late-gestation mice and death of pregnant mice (mortality rates of 60% and 20%, respectively), which may be attributed to the presence of isoborneol in synthetic borneol (Li et al., 2021). Studies on the correlation between physiological and toxicological properties of borneol enantiomers are limited.
Pediatric Concerns
The chemical constitution of camphor exhibits a degree of toxicity, particularly its adverse impact on the health of infants and young children. As a result, certain countries have implemented strict regulations on the necessity to utilize camphor and its related compounds, with requirements for careful usage.
Interactions with Co-Administered Drugs
Borneol is believed to improve the blood concentration and bioavailability of drugs, and has been paired with various TCM formulas since ancient times. This permeation-enhancing property, while therapeutically sought-after, carries the implication that borneol may alter the pharmacokinetics of co-administered pharmaceuticals in unpredictable ways at the blood–brain barrier, intestinal barrier, and skin. L-borneol exhibits a stronger binding affinity for the CYP2C9 target, which may be associated with its anti-myocardial ischemia effects through the regulation of arachidonic acid metabolism. CYP2C9 involvement raises the theoretical possibility of drug–drug interactions with CYP2C9 substrates, though this has not been adequately characterized in humans.
Evidence Limitations
The pharmacological properties and applications of borneol are promising, including anti-inflammatory, analgesic, antimicrobial, and antioxidant properties, as well as enhancing drug delivery and treating cardiovascular diseases. However, its clinical application is hindered by the limited research on safety, efficacy, and pharmacokinetics. More extensive preclinical and mainly clinical studies are warranted before this bicyclic monoterpene can be established as an active pharmaceutical agent.
References
Go back